Parvovirus B19 VLP VP1/VP2 Co-Capsid

Added to your cart

Parvovirus B19 VLP VP1/VP2 Co-Capsid

Cart subtotal: £0.00

View cart (0) Checkout

#SKU 48100

Get in touch to purchase this product

Contact our team of experts to discuss your requirements

Contact our expert team

Product Details

Parvovirus B19 propagates primarily in erythroid progenitor cells and is the causative agent of erythema infectiosum. The viral capsid comprises a major and a minor structural protein, named VP2 and VP1, respectively. DIARECT offers recombinant VP1 and VP2 co-assembled into virus like particles (VLP).
0.1 mg
48100

More information

Attributes

Description

  • Shipping Information
  • Dry ice
  • Abbreviations
  • VLP VP1/VP2
  • Recommended Use
  • RUO
  • Storage
  • -70°C or below
  • Shelf Life
  • 5 years from DOM
  • Disease Area
  • Erythema infectiosum
  • Source
  • Baculovirus/Insect cells

Technical Documents

MSDS P B19 VLP VP1 VP2 48100 210426 Rev03 (55.89KB)

Product Specification (23.81KB)

Safety Data Sheet (55.89KB)

Sorry, no results found.

Enter the full lot number and hit enter.

BBI Solutions Brands

diarect.png

The acquisition of DIARECT in June 2020 and their world leading recombinant autoimmune antigen capability immediately enhances BBI’s portfolio and position as a ‘complete’ immunoassay reagent supplier. This further enhances BBI’s position as the world’s largest diagnostics components company with a market leading antigen portfolio.

mbs.png

Maine Biotechnology Services brings 27 years of knowledge, experience, process development, and project management to our customers to ensure the best possible antibodies for any application. As antibody development goals in the biotechnology and pharmaceutical industry have evolved the acquisition of MBS will help BBI further meet and exceed our customers needs.

Newsletter

Signup for our newsletter to receive the latest BBI Solutions updates and special offers in your inbox